8-K: Enzo Biochem to Voluntarily Delist from NYSE, Transfer to OTCQX

Enzo Biochem announces its intention to voluntarily delist from the New York Stock Exchange (NYSE) and move its trading to the OTCQX Best Market.

Summary

• Enzo Biochem, Inc. has announced its decision to voluntarily delist its common stock from the New York Stock Exchange (NYSE).
• The company intends to have its common stock quoted on the OTCQX Best Market (OTCQX).
• Enzo provided notice to the NYSE on March 28, 2025, and plans to file Form 25 with the SEC around April 7, 2025.
• The delisting is expected to be effective around April 17, 2025, with trading on OTCQX commencing around April 18, 2025, pending OTCQX approval.
• The company's decision follows a notice from the NYSE regarding non-compliance with continued listing standards related to market capitalization, stockholders' equity, and average closing stock price.
• Shareholders will not be required to exchange any shares, and electronic trading is expected to continue without material disruption.
• Enzo Biochem will remain subject to the periodic reporting requirements of the Securities Exchange Act of 1934.

Sentiment

Score: 4

Explanation: The sentiment is somewhat negative due to the delisting from the NYSE, which is generally perceived as a setback. However, the company is attempting to mitigate the impact by transitioning to OTCQX and ensuring continuity of trading for shareholders.

Positives

• Shareholders will not be required to exchange any shares during the transition.
• Electronic trading is expected to be available without any material disruption.
• The company will remain subject to the periodic reporting requirements of the Securities Exchange Act of 1934.

Negatives

• The company received a notice from the NYSE regarding non-compliance with continued listing standards related to market capitalization, stockholders' equity, and average closing stock price.
• The delisting from a major exchange like NYSE could potentially reduce the visibility and prestige of the company's stock.

Risks

• The company's ability to successfully transfer to OTCQX is subject to approval.
• There is a possibility that the company's common stock may be involuntarily delisted from the NYSE prior to the effectiveness of the voluntary delisting.
• Market conditions could impact the trading and price of the company's common stock.
• The company faces risks described in the Risk Factors section of its Annual Report on Form 10-K for the year ended July 31, 2024, and in its other subsequent filings with the SEC.

Future Outlook

The company expects its common stock to be quoted on the OTCQX on or about April 18, 2025, subject to approval. They will remain subject to the periodic reporting requirements of the Securities Exchange Act of 1934.

Management Comments

• The Board of Directors has determined to voluntarily delist the Company's common stock from the NYSE and transfer trading of the common stock to the OTCQX at this time rather than continuing activity with the NYSE's listing requirements.

Industry Context

Companies that fail to meet the listing requirements of major exchanges like the NYSE sometimes choose to delist and trade on over-the-counter markets like OTCQX to avoid the costs and regulatory burdens associated with maintaining a listing on a major exchange. This is often seen when a company's market capitalization or stock price falls below the required thresholds.

Comparison to Industry Standards

• Many smaller biotech companies with limited trading volume or market capitalization have chosen to trade on the OTCQX or OTCQB markets.
• This move is similar to decisions made by companies like Generex Biotechnology and others who found the requirements of major exchanges too burdensome given their financial situations.
• Compared to companies like Amarin Corporation, which successfully maintained its NASDAQ listing despite challenges, Enzo's decision reflects a different strategic choice given its circumstances.

Stakeholder Impact

• Shareholders may experience a change in trading venue, but electronic trading is expected to continue without material disruption.
• Employees may be affected by the company's financial situation and strategic shift.
• The company's suppliers and customers may be indirectly affected by the company's overall performance and market perception.

Next Steps

• File a notification of removal from listing on Form 25 with the SEC on or about April 7, 2025.
• Obtain approval from the OTCQX for the quotation of the common stock.
• Commence trading on the OTCQX on or about April 18, 2025.

Key Dates

Keywords

delisting, OTCQX, NYSE, Enzo Biochem, common stock, trading, listing standards